Genetic polymorphism of the tissue inhibitor of metalloproteinase-1 is associated with an increased risk of endometrial cancer

Clinica Chimica Acta

Volumn 409, Issue 1-2, 2009, Pages 127-131

  Yi, Yu Chiao ^a,b   Chen, Mu Kuan ^c,d   Chen, Ling Yun ^b   Ho, Esther Shih Chu ^a,e   Ying, Tsung Ho ^b,f   Wang, Po Hui ^b,f   Yang, Shun Fa ^b,f  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d MINGDAO UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Endometrial cancer; Polymorphism; Tissue inhibitors of metalloproteinases

Indexed keywords

CYSTEINE; GLYCINE; MESSENGER RNA; THREONINE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; UPREGULATION;

CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 70349822966     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.09.015     Document Type: Article

References (41)

1. Lapinska S., Olszewski J., Makarewicz H., Emerich J., and Debniak J. A clinical analysis of risk factors in women operated because of endometrial cancer. Ginekol Pol 69 (1998) 252-257
2. Weiss J.M., Saltzman B.S., Doherty J.A., et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 164 (2006) 56-62
3. Nishioka Y., Kobayashi K., Sagae S., et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 91 (2000) 612-615
4. Sugimoto M., Yoshida S., Kennedy S., Deguchi M., Ohara N., and Maruo T. Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig 13 (2006) 523-529
5. Kubben F.J., Sier C.F., Meijer M.J., et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 95 (2006) 744-751
6. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 19 (1999) 1589-1592
7. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
8. DeClerck Y.A., and Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A (1994) 2170-2180
9. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 86 (1994) 299-304
10. Montgomery A.M., Mueller B.M., Reisfeld R.A., Taylor S.M., and DeClerck Y.A. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54 (1994) 5467-5473
11. POC, Rhys-Evans P., Modjtahedi H., Court W., Box G., and Eccles S. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 86 (2000) 307-317
12. Lokeshwar B.L., Selzer M.G., Block N.L., and Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53 (1993) 4493-4498
13. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., and Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298 (1992) 29-32
14. Guedez L., McMarlin A.J., Kingma D.W., Bennett T.A., Stetler-Stevenson M., and Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 158 (2001) 1207-1215
15. Yoshiji H., Harris S.R., Raso E., et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75 (1998) 81-87
16. Goss K.J., Brown P.D., and Matrisian L.M. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78 (1998) 629-635
17. Lee S.J., Yoo H.J., Bae Y.S., Kim H.J., and Lee S.T. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 312 (2003) 1196-1201
18. Rho S.B., Chung B.M., and Lee J.H. TIMP-1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF. J Cell Biochem 101 (2007) 57-67
19. Valente P., Fassina G., Melchiori A., et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 75 (1998) 246-253
20. Ree A.H., Florenes V.A., Berg J.P., Maelandsmo G.M., Nesland J.M., and Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 3 (1997) 1623-1628
21. Nakopoulou L., Giannopoulou I., Stefanaki K., et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 197 (2002) 307-313
22. Schrohl A.S., Christensen I.J., Pedersen A.N., et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2 (2003) 164-172
23. Guedez L., Mansoor A., Birkedal-Hansen B., et al. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood 97 (2001) 1796-1802
24. Li G., Fridman R., and Kim H.R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59 (1999) 6267-6275
25. Docherty A.J., Lyons A., Smith B.J., et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318 (1985) 66-69
26. Hinterseher I., Krex D., Kuhlisch E., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm. World J Surg 31 (2007) 2248-2254
27. Meijer M.J., Mieremet-Ooms M.A., van Hogezand R.A., Lamers C.B., Hommes D.W., and Verspaget H.W. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 13 (2007) 2960-2966
28. Indelicato M., Chiarenza V., Libra M., et al. Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients. J Clin Lab Anal 20 (2006) 173-176
29. Wei JC, Lee HS, Chen WC, Shiu LJ, Yang SF, Wong RH. Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis. Ann Rheum Dis in press.
30. Anderson C.L., and Brown C.J. Polymorphic X-chromosome inactivation of the human TIMP1 gene. Am J Hum Genet 65 (1999) 699-708
31. Hamasaki T., Hattori T., Kimura G., and Nakazawa N. Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells. Urol Res 26 (1998) 371-376
32. Kugler A., Hemmerlein B., Thelen P., Kallerhoff M., Radzun H.J., and Ringert R.H. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160 (1998) 1914-1918
33. Mukai M., Sadahiro S., Tokunaga N., et al. The expression of MMP-2 and TIMP-2 in patients with colorectal adenocarcinoma invaded to the submucosal and proper muscle layer. Oncol Rep 5 (1998) 335-340
34. Krex D., Rohl H., Konig I.R., Ziegler A., Schackert H.K., and Schackert G. Tissue inhibitor of metalloproteinases-1, -2, and -3 polymorphisms in a white population with intracranial aneurysms. Stroke 34 (2003) 2817-2821
35. Hirano K., Sakamoto T., Uchida Y., et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 18 (2001) 748-752
36. Hegab A.E., Sakamoto T., Uchida Y., et al. Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms. Respirology 10 (2005) 27-30
37. Kang S., Zhao X., Xing H., et al. Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis. Environ Mol Mutagen 49 (2008) 226-231
38. Roca F., Mauro L.V., Morandi A., et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 93 (2006) 151-160
39. O-Charoenrat P., and Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42 (2006) 257-267
40. Vairaktaris E., Yapijakis C., Yiannopoulos A., et al. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17 (2007) 963-968
41. Yang L., Gu H.J., Zhu H.J., et al. Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. Eur J Surg Oncol 34 (2008) 636-641